This article is more than 5 years old. Information may no longer be current.

Inotek receives US patent for trabodenoson, prostaglandin analogue for reduction of IOP

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

The United States Patent and Trademark Office has issued a composition of matter patent for trabodenoson in combination with a prostaglandin analogue for reducing IOP in patients with glaucoma, according to a press release.

U.S. patent No. 9,370,530 includes composition of matter intellectual property protection for the use of trabodenoson (Inotek) in combination with a prostaglandin analogue until 2031. The patent also includes composition of matter patents covering the trabodenoson compound in the U.S. until 2026 and abroad until 2025, and the crystalline formulation of trabodenoson used in eye drops in the U.S. until 2033.

Furthermore, patents relating to the use of trabodenoson for reducing IOP in the U.S. will expire in 2031, and if issued abroad, 2030.

“[The patent] protects use of the combination of trabodenoson with any prostaglandin analogue in a single, convenient daily eye drop,” David P. Southwell, president and CEO of Inotek, said in the release. “We look forward to reporting data from our recently initiated phase 2 [fixed-dose combination] trial of trabodenoson and the most commonly used prostaglandin, latanoprost, in the second half of 2017.”